Nightstar Therapeutics (NITE) Price Target Increased to $24.00 by Analysts at Mizuho
Nightstar Therapeutics (NASDAQ:NITE) had its target price upped by Mizuho to $24.00 in a research report report published on Tuesday morning, The Fly reports. They currently have a buy rating on the stock.
A number of other analysts have also recently commented on the stock. Zacks Investment Research cut shares of Nightstar Therapeutics from a hold rating to a sell rating in a research note on Wednesday, June 6th. Janney Montgomery Scott started coverage on shares of Nightstar Therapeutics in a research note on Wednesday, August 22nd. They set a buy rating and a $34.00 price target on the stock. Chardan Capital restated a buy rating and set a $40.00 price target on shares of Nightstar Therapeutics in a research note on Wednesday, June 6th. Finally, UBS Group cut shares of Nightstar Therapeutics from an outperform rating to a market perform rating in a research note on Wednesday, June 27th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and an average price target of $29.86.
NITE opened at $21.25 on Tuesday. The stock has a market capitalization of $604.15 million and a price-to-earnings ratio of -13.04. Nightstar Therapeutics has a twelve month low of $10.01 and a twelve month high of $24.93.
Several hedge funds have recently made changes to their positions in NITE. Millennium Management LLC purchased a new stake in shares of Nightstar Therapeutics during the 1st quarter valued at approximately $507,000. Stanley Laman Group Ltd. bought a new stake in Nightstar Therapeutics during the 2nd quarter worth approximately $195,000. Woodford Investment Management Ltd bought a new stake in Nightstar Therapeutics during the 2nd quarter worth approximately $5,024,000. Bank of America Corp DE bought a new stake in Nightstar Therapeutics during the 2nd quarter worth approximately $132,000. Finally, Redmile Group LLC increased its holdings in Nightstar Therapeutics by 0.9% during the 2nd quarter. Redmile Group LLC now owns 1,785,446 shares of the company’s stock worth $28,567,000 after acquiring an additional 16,500 shares during the period. Institutional investors own 28.62% of the company’s stock.
About Nightstar Therapeutics
Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.
Recommended Story: Technical Analysis
Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.